Viatris and ocuphire pharma announce fda approval of ryzumvl™ (phentolamine ophthalmic solution) 0.75% eye drops for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g.

Ryzumvi expected to be commercially available in the u.s. in the first half of 2024   pittsburgh, and farmington hills, mich. , sept. 27, 2023 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, and ocuphire pharma, inc. (nasdaq: ocup), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the u.s. food and drug administration (fda) has approved ryzumvi™  (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g.
VTRS Ratings Summary
VTRS Quant Ranking